**Supplement 2.** Two supplementary tables.

|  |  |  |  |
| --- | --- | --- | --- |
| Supplementary Table 1*.* Patient and clinical characteristics by choice of anesthetic in the restricted propensity score (PS) matched cohort | | | |
|  | | | |
|  | **Restricted**  **PS matched cohort** | | |
|  | **Inhaled volatiles** | **Propofol** | **Standardized mean difference** |
|  | **n (%)** | **n (%)** |
| **Total number of subjects** | 4660 (100.0) | 4660 (100.0) |  |
| **Age at surgery, median (Inter Quartile Range)** | 67.0 (55.0-74.0) | 66.0 (57.0-73.3) | 0.025 |
| **Gender, female** | - | - |  |
| **ASA classification** |  |  | 0.028 |
| ASA 1 | 1204 (25.8) | 1188 (25.5) |  |
| ASA 2 | 2575 (55.3) | 2633 (56.5) |  |
| ASA 3-5 | 881 (18.9) | 839 (18.0) |  |
| **Local/regional anesthesia** |  |  |  |
| Regional block | - | - |  |
| Wound infiltration | - | - |  |
| **Year of surgery, median (Inter Quartile Range)** | 2017 (2016-2018) | 2017 (2016-2018) | 0.046 |
| **Surgery volume** |  |  | 0.052 |
| < 100 surgeries | 138 ( 3.0) | 112 ( 2.4) |  |
| 100-500 surgeries | 198 ( 4.2) | 164 ( 3.5) |  |
| 500+ surgeries | 4324 (92.8) | 4384 (94.1) |  |
| **Diagnosed at screening** | 2160 (46.4) | 2371 (50.9) | 0.091 |
| **Tumor/Metastasis/Node-staging** |  |  |  |
| T1 | - | - |  |
| T2 | - | - |  |
| T3 | - | - |  |
| T4 | - | - |  |
| **Node stage** |  |  |  |
| N0 | - | - |  |
| N1-N3 | - | - |  |
| NX | - | - |  |
| **Metastasis stage** |  |  |  |
| M0 | - | - |  |
| M1 | - | - |  |
| MX | - | - |  |
| **Estrogen Receptor status** |  |  | 0.065 |
| Postive | 3631 (77.9) | 3739 (80.2) |  |
| Negative | 947 (20.3) | 844 (18.1) |  |
| Not Performed | 32 ( 0.7) | 39 ( 0.8) |  |
| Missing | 50 ( 1.1) | 38 ( 0.8) |  |
| **Progesteron Receptor status** |  |  |  |
| Postive | - | - |  |
| Negative | - | - |  |
| Not Performed | - | - |  |
| Missing | - | - |  |
| **Nuclear antigen, marker of proliferation status** |  |  | 0.061 |
| Low | 2052 (44.0) | 2190 (47.0) |  |
| Intermediate | 412 ( 8.8) | 403 ( 8.6) |  |
| High | 1725 (37.0) | 1636 (35.1) |  |
| Not Performed | 471 (10.1) | 431 ( 9.2) |  |
| **Human Epidermal growth factor Receptor 2 status** |  |  | 0.055 |
| 0-1+ | 2717 (58.3) | 2827 (60.7) |  |
| 2+ | 888 (19.1) | 863 (18.5) |  |
| 3+ | 312 ( 6.7) | 269 ( 5.8) |  |
| Not performed | 743 (15.9) | 701 (15.0) |  |
| **Adjuvant treatment** |  |  |  |
| Chemotherapy | - | - |  |
| Radiotherapy | - | - |  |
| Endocrine therapy | - | - |  |
| Antibodies | - | - |  |
| **Main reason for surgery** |  |  | 0.040 |
| Breast Conserving Therapy | 2902 (62.3) | 2958 (63.5) |  |
| Mastectomy | 1310 (28.1) | 1304 (28.0) |  |
| Modified radical mastectomy | 442 ( 9.5) | 394 ( 8.5) |  |
| Surgery of relapses | 6 ( 0.1) | 4 ( 0.1) |  |
| **Post surgery treatment** |  |  |  |
| Chemotherapy | - | - |  |
| Radiotherapy | - | - |  |
| Endocrine therapy | - | - |  |
| Antibodies | - | - |  |
|  |  |  |  |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Supplementary Table 2. Three- and five-year overall survival and overall mortality expressed as Hazard Ratios (HR) with 95% CI by choice of anesthetic for the restricted PS matched cohort. | | | | | | | | | | | | | | | | | |
|  | |
|  |  |  |  |  |  |  |  |  |  |  |  |  | |  | |  |  | |
|  | **Three year survival** | | | | |  | **Five year survival** | | | | | |  | | **Overall mortality** | | |  | |
|  | **Events** | **At risk** | **3 year** | **95% CI** | ***P*-value** |  | **Events** | **At risk** | **5 year** | **95% CI** | ***P*-value** |  | | **HR** | | **95% CI** |  | |
| **Restricted**  **PS Matched** |  |  |  |  |  |  |  |  |  |  |  |  | |  | |  |  | |
| Inhaled volatiles | 185 | 2158 | 91.4 | 90.4-92.3 | 0.496 |  | 57 | 451 | 87.3 | 85.8-88.8 | 0.642 |  | | 1.00 | | reference |  | |
| Propofol | 175 | 2189 | 92.0 | 91.1-92.9 |  | 86 | 610 | 85.8 | 84.3-87.4 |  | | 1.04 | | 0.90-1.19 |  | |
|  |  |  |  |  |  |  |  |  |  |  |  |  | |  | |  |  | |